Renoprotective effects of Vitamin D and renin-angiotensin system

Hippokratia

Volumn 15, Issue 4, 2011, Pages 308-311

  Koroshi, A ^a   Idrizi, A ^a  

^a UNIVERSITY HOSPITAL CENTER MOTHER TERESA   (Albania)

Author keywords

Angiotensin II; Chronic kidney disease review; Renin angiotensin system; Vitamin D

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCITRIOL; LOSARTAN; PARICALCITOL; PLACEBO; RENIN; RENIN ANGIOTENSIN SYSTEM BLOCKER; RENIN INHIBITOR; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG MECHANISM; GLOMERULOSCLEROSIS; HEMODYNAMICS; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; KIDNEY FAILURE; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

EID: 80053454298     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihy-droxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110: 229-238.
2. Yoshizawa, T. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet. 1997; 16:391-396.
3. Panda DK. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA. 2001; 98:7498-7503.
4. Li YC Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA. 1997; 94: 9831-9835.
5. Dardenne O, Prud'homme J, Arabian A, Glorieux FH, St-Ar-naud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1-(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology. 2001; 142:3135-3141.
6. Agarwal R. Vitamin D, Proteinuria, Diabetic Nephropathy and Progression of CKD. Clin J Am Soc Nephrology. 2009; 4: 1523-1528.
7. Muller D, Muller DN. Battle against the rennin-angiotensin system: help from an unexpected party. Nephrology Dialysis Transplantation. 2009; 24;1110-1112.
8. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-Hydroxyvitamin D Levels, Race, and the Progression of Kidney Disease. J Am Soc Nephrology. 2009; 20: 2631-2639.
9. Martin RJ, McKnight AJ, Patterson CC, Sadlier DM, Maxwell AP, Warren 3/UK GoKinD Study Group. A rare haplotype of the vitamin D receptor gene is protective against diabetic nephropa-thy. Nephrol Dia. Transplant. 2010. 25: 497-503.
10. Scrag R, Soers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National and Nutrition Examination Survey. Am J Hypertension. 2007; 20: 713-719.
11. Bodyak N, Ayus JC, Achinger S. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt sensitive animals. Proc Natl Acad Sci USA. 2007; 104: 16801-16815.
12. Fitzsimons JT. Angiotensin stimulation of the central nervous system. Rev Physiol Biochem Pharmacol. 1980; 87:117-167.
13. Geisterfer, AA, Peach, MJ, Owens, GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988; 62:749-756.
14. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy blockade of compensatory ren-nin increase. Proc Natl Acad Sci USA. 2008;41:15896-15901.
15. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y et al. Combined vitamin D analog and AT1 receptor antagonist syner-gically block the development of of kidney disease in a model of type 2 diabetes. Kidn Int. 2010;77:1000-1009.
16. Agarwal R. Are vitamin D receptor agonists like angiotensin-convering enzyme inhibitors without side effects? Kidn Int. 2010; 77: 943-945.
17. Li YC. Vitamin D regulation of the Renin Angiotensin System. Journal of Cellular Biochemistry. 2003; 88: 323-331.
18. Rostand SG. Ultraviolet light may contribute to geographic and racial blod pressure differences. Hypertension. 1997; 30: 150-156.
19. Krause R, Buhring M, Hopfenmuller W et al. Ultraviolet B and blood pressure. Lancet. 1998; 352: 709-710.
20. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidn Int. 2005; 68: 2823-2828.
21. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double blind pilot trial. Hypertension. 2008; 52: 249-255.
22. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. Oral calcitriol for the treatment of persistent proteinuria in im-munoglobulin A nephropathy: an un controlled trial. Am J Kidn Dis. 2008;51: 724-731.
23. Fishbane S, Chittienni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and pro-teinuria: a randomized trial. Am J Kidn Di.s 2009; 54: 647-652.
24. Cheng HF. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol 2001; 280: F449-F456.
25. Bodyak N, Ayus JC, Achinger S, shivalingappa V, Ke Q, Chen YS et al. Activated vitamin D attenuates left ventricular abnormalities induced bu dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA. 2007; 104: 16810-16815.
26. Wolf M. Betancourt J, Chang, Y, Shah A, Teng M, Tamez H et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008; 19:1379-1388.